Galactolipid deficiency in the early pathogenesis of neuronal ceroid lipofuscinosis model Cln8mnd: Implications to delayed myelination and oligodendrocyte maturation

Neuropathology and Applied Neurobiology

Volumn 38, Issue 5, 2012, Pages 471-486

  Kuronen, M ^a,b   Hermansson, M ^c   Manninen, O ^a,b   Zech, I ^e   Talvitie, M ^a,b   Laitinen, T ^d   Grohn O ^d   Somerharju, P ^b   Eckhardt, M ^e   Cooper, J D ^f   Lehesjoki, A E ^a,b   Lahtinen, U ^a,b   Kopra, O ^a,b  

^a FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF BONN   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Batten disease; Cerebroside; Galactosylceramide; Myelin; Oligodendrocyte; Sulphatide

Indexed keywords

BIOLOGICAL MARKER; GALACTOLIPID; GALACTOSYLCERAMIDE; GANGLIOSIDE GALACTOSYLTRANSFERASE; MESSENGER RNA; MYELIN; SULFATIDE; TUBULIN; URIDINE DIPHOSPHATE GALACTOSE;

ANIMAL TISSUE; ANTERIOR COMMISSURE; ARTICLE; BRAIN TISSUE; CLN8 GENE; CONTROLLED STUDY; CORPUS CALLOSUM; ELECTRON MICROSCOPY; EMBRYO; ENZYME ACTIVITY; GALACTOLIPID DEFICIENCY; GENE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPID COMPOSITION; LIPID METABOLISM; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLIC DISORDER; MOUSE; MYELINATION; NERVE CELL DIFFERENTIATION; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; WHITE MATTER;

ANIMALS; AXONS; BRAIN; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MYELIN SHEATH; NEURONAL CEROID-LIPOFUSCINOSES; OLIGODENDROGLIA; TIME FACTORS;

EID: 84863469926     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2011.01233.x     Document Type: Article

References (65)

1. Haltia M. The neuronal ceroid-lipofuscinoses: from past to present. Biochim Biophys Acta 2006; 1762: 850-6.
2. Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 2002; 70: 324-35.
3. The International Batten Disease Consortium. Isolation of a novel gene underlying Batten disease, CLN3. Cell 1995; 82: 949-57.
4. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, Liu XQ, Wilson C, Lahtinen U, Anttonen AK, Lehesjoki AE. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet 2007; 81: 136-46.
5. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, Lehesjoki AE, Tyynela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. Brain 2006; 129: 1438-45.
6. Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet 1998; 19: 286-8.
7. Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole S, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, Lehesjoki AE. The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat Genet 1999; 23: 233-6.
8. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997; 277: 1802-5.
9. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995; 376: 584-7.
10. Noskova L, Stranecky V, Hartmannova H, Pristoupilova A, Baresova V, Ivanek R, Hulkova H, Jahnova H, van der Zee J, Staropoli JF, Sims KB, Tyynela J, Van Broeckhoven C, Nijssen PC, Mole SE, Elleder M, Kmoch S. Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. Am J Hum Genet 2011; 89: 241-52.
11. Hirvasniemi A, Lang H, Lehesjoki AE, Leisti J. Northern epilepsy syndrome: an inherited childhood onset epilepsy with associated mental deterioration. J Med Genet 1994; 31: 177-82.
12. Cannelli N, Cassandrini D, Bertini E, Striano P, Fusco L, Gaggero R, Specchio N, Biancheri R, Vigevano F, Bruno C, Simonati A, Zara F, Santorelli FM. Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranean. Neurogenetics 2006; 7: 111-17.
13. Zelnik N, Mahajna M, Iancu TC, Sharony R, Zeigler M. A novel mutation of the CLN8 gene: is there a Mediterranean phenotype? Pediatr Neurol 2007; 36: 411-13.
14. Vantaggiato C, Redaelli F, Falcone S, Perrotta C, Tonelli A, Bondioni S, Morbin M, Riva D, Saletti V, Bonaglia MC, Giorda R, Bresolin N, Clementi E, Bassi MT. A novel CLN8 mutation in late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) reveals aspects of CLN8 neurobiological function. Hum Mutat 2009; 30: 1104-16.
15. Topcu M, Tan H, Yalnizoglu D, Usubutun A, Saatci I, Aynaci M, Anlar B, Topaloglu H, Turanli G, Kose G, Aysun S. Evaluation of 36 patients from Turkey with neuronal ceroid lipofuscinosis: clinical, neurophysiological, neuroradiological and histopathologic studies. Turk J Pediatr 2004; 46: 1-10.
16. Ranta S, Topcu M, Tegelberg S, Tan H, Ustubutun A, Saatci I, Dufke A, Enders H, Pohl K, Alembik Y, Mitchell WA, Mole SE, Lehesjoki AE. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat 2004; 23: 300-5.
17. Reinhardt K, Grapp M, Schlachter K, Bruck W, Gartner J, Steinfeld R. Novel CLN8 mutations confirm the clinical and ethnic diversity of late infantile neuronal ceroid lipofuscinosis. Clin Genet 2010; 77: 79-85.
18. Kousi M, Siintola E, Dvorakova L, Vlaskova H, Turnbull J, Topcu M, Yuksel D, Gokben S, Minassian BA, Elleder M, Mole SE, Lehesjoki AE. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. Brain 2009; 132: 810-19.
19. Messer A, Flaherty L. Autosomal dominance in a late-onset motor neuron disease in the mouse. J Neurogenet 1986; 3: 345-55.
20. Bronson RT, Lake BD, Cook S, Taylor S, Davisson MT. Motor neuron degeneration of mice is a model of neuronal ceroid lipofuscinosis (Batten's disease). Ann Neurol 1993; 33: 381-5.
21. Cooper JD, Messer A, Feng AK, Chua-Couzens J, Mobley WC. Apparent loss and hypertrophy of interneurons in a mouse model of neuronal ceroid lipofuscinosis: evidence for partial response to insulin-like growth factor-1 treatment. J Neurosci 1999; 19: 2556-67.
22. Battaglioli G, Martin DL, Plummer J, Messer A. Synaptosomal glutamate uptake declines progressively in the spinal cord of a mutant mouse with motor neuron disease. J Neurochem 1993; 60: 1567-9.
23. Bertamini M, Marzani B, Guarneri R, Guarneri P, Bigini P, Mennini T, Curti D. Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. Eur J Neurosci 2002; 16: 2291-6.
24. Guarneri R, Russo D, Cascio C, D'Agostino S, Galizzi G, Bigini P, Mennini T, Guarneri P. Retinal oxidation, apoptosis and age- and sex-differences in the mnd mutant mouse, a model of neuronal ceroid lipofuscinosis. Brain Res 2004; 1014: 209-20.
25. Mennini T, Bastone A, Crespi D, Comoletti D, Manzoni C. Spinal cord GLT-1 glutamate transporter and blood glutamic acid alterations in motor neuron degeneration (Mnd) mice. J Neurol Sci 1998; 157: 31-6.
26. Mennini T, Bigini P, Ravizza T, Vezzani A, Calvaresi N, Tortarolo M, Bendotti C. Expression of glutamate receptor subtypes in the spinal cord of control and mnd mice, a model of motor neuron disorder. J Neurosci Res 2002; 70: 553-60.
27. Vance JE, Stone SJ, Faust JR. Abnormalities in mitochondria-associated membranes and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of neuronal ceroid lipofuscinosis. Biochim Biophys Acta 1997; 1344: 286-99.
28. Lonka L, Kyttala A, Ranta S, Jalanko A, Lehesjoki AE. The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. Hum Mol Genet 2000; 9: 1691-7.
29. Lonka L, Salonen T, Siintola E, Kopra O, Lehesjoki AE, Jalanko A. Localization of wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in non-neuronal and neuronal cells. J Neurosci Res 2004; 76: 862-71.
30. Winter E, Ponting CP. TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing domains? Trends Biochem Sci 2002; 27: 381-3.
31. Hermansson M, Kakela R, Berghall M, Lehesjoki AE, Somerharju P, Lahtinen U. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study. J Neurochem 2005; 95: 609-17.
32. Hermansson M, Uphoff A, Kakela R, Somerharju P. Automated quantitative analysis of complex lipidomes by liquid chromatography/mass spectrometry. Anal Chem 2005; 77: 2166-75.
33. Zoller I, Bussow H, Gieselmann V, Eckhardt M. Oligodendrocyte-specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT-deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide level. Glia 2005; 52: 190-8.
34. Bible E, Gupta P, Hofmann SL, Cooper JD. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 2004; 16: 346-59.
35. Kielar C, Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA, Wong M, Sands MS, Cooper JD. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 2007; 25: 150-62.
36. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates 2nd edn. San Diego, CA: Academic Press, 2001.
37. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987; 147: 229-63.
38. Basser PJ, Pierpaoli C. A simplified method to measure the diffusion tensor from seven MR images. Magn Reson Med 1998; 39: 928-34.
39. Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, Aalto A, Huopaniemi L, Aula N, Michellucci R, Eriksson K, Lehesjoki AE. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet 2007; 15: 185-93.
40. Heinonen O, Kyttala A, Lehmus E, Paunio T, Peltonen L, Jalanko A. Expression of palmitoyl protein thioesterase in neurons. Mol Genet Metab 2000; 69: 123-9.
41. Pedraza CE, Monk R, Lei J, Hao Q, Macklin WB. Production, characterization, and efficient transfection of highly pure oligodendrocyte precursor cultures from mouse embryonic neural progenitors. Glia 2008; 56: 1339-52.
42. Alexander AL, Lee JE, Lazar M, Field AS. Diffusion tensor imaging of the brain. Neurother 2007; 4: 316-29.
43. Lonka L, Aalto A, Kopra O, Kuronen M, Kokaia Z, Saarma M, Lehesjoki AE. The neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated in mouse brain and up-regulated in the hippocampal kindling model of epilepsy. BMC Neurosci 2005; 6: 27.
44. Messer A, Plummer J, Wong V, Lavail MM. Retinal degeneration in motor neuron degeneration (mnd) mutant mice. Exp Eye Res 1993; 57: 637-41.
45. Bolivar VJ, Scott Ganus J, Messer A. The development of behavioral abnormalities in the motor neuron degeneration (mnd) mouse. Brain Res 2002; 937: 74-82.
46. Boyce S, Webb JK, Carlson E, Rupniak NM, Hill RG, Martin JE. Onset and progression of motor deficits in motor neuron degeneration (mnd) mice are unaltered by the glycine/NMDA receptor antagonist L-701, 324 or the MAO-B inhibitor R(-)-deprenyl. Exp Neurol 1999; 155: 49-58.
47. Plummer J, Peterson A, Messer A. Accelerated and widespread neuronal loss occurs in motor neuron degeneration (mnd) mice expressing a neurofilament-disrupting transgene. Mol Cell Neurosci 1995; 6: 532-43.
48. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci 2008; 28: 264-78.
49. Wegner M. A matter of identity: transcriptional control in oligodendrocytes. J Mol Neurosci 2008; 35: 3-12.
50. Quarles RH. Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell Mol Life Sci 2002; 59: 1851-71.
51. Futerman AH, Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol 2005; 15: 312-18.
52. Guillas I, Jiang JC, Vionnet C, Roubaty C, Uldry D, Chuard R, Wang J, Jazwinski SM, Conzelmann A. Human homologues of LAG1 reconstitute Acyl-CoA-dependent ceramide synthesis in yeast. J Biol Chem 2003; 278: 37083-91.
53. Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr Res 2008; 63: 625-31.
54. Bradl M, Lassmann H. Oligodendrocytes: biology and pathology. Acta Neuropathol 2010; 119: 37-53.
55. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008; 60: 430-40.
56. Bauer NG, Richter-Landsberg C, Ffrench-Constant C. Role of the oligodendroglial cytoskeleton in differentiation and myelination. Glia 2009; 57: 1691-705.
57. Jalanko A, Braulke T. Neuronal ceroid lipofuscinoses. Biochim Biophys Acta 2009; 1793: 697-709.
58. Lin W, Popko B. Endoplasmic reticulum stress in disorders of myelinating cells. Nat Neurosci 2009; 12: 379-85.
59. Galizzi G, Russo D, Deidda I, Cascio C, Passantino R, Guarneri R, Bigini P, Mennini T, Drago G, Guarneri P. Different early ER-stress responses in the CLN8(mnd) mouse model of neuronal ceroid lipofuscinosis. Neurosci Lett 2011; 488: 258-62.
60. Boggs JM, Gao W, Zhao J, Park HJ, Liu Y, Basu A. Participation of galactosylceramide and sulfatide in glycosynapses between oligodendrocyte or myelin membranes. FEBS Lett 2010; 584: 1771-8.
61. Striano P, Specchio N, Biancheri R, Cannelli N, Simonati A, Cassandrini D, Rossi A, Bruno C, Fusco L, Gaggero R, Vigevano F, Bertini E, Zara F, Santorelli FM, Striano S. Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy Behav 2007; 10: 187-91.
62. Chu-LaGraff Q, Blanchette C, O'Hern P, Denefrio C. The Batten disease Palmitoyl Protein Thioesterase 1 gene regulates neural specification and axon connectivity during Drosophila embryonic development. PLoS ONE 2010; 5: e14402.
63. Kielar C, Wishart TM, Palmer A, Dihanich S, Wong AM, Macauley SL, Chan CH, Sands MS, Pearce DA, Cooper JD, Gillingwater TH. Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease. Hum Mol Genet 2009; 18: 4066-80.
64. Takahashi N, Sakurai T, Davis KL, Buxbaum JD. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 2011; 93: 13-24.
65. Desai MK, Sudol KL, Janelsins MC, Mastrangelo MA, Frazer ME, Bowers WJ. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009; 57: 54-65.